CEA-Targeting CAR Construct with Checkpoint Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR-T cell therapy for solid tumors faces challenges such as inadequate tumor specificity, heterogeneity of tumor antigens leading to resistance, and an immunosuppressive tumor microenvironment, resulting in limited efficacy and adverse side effects.
Innovation Solution
Genetically modified cells expressing a recombinant nucleic acid construct with a chimeric antigen receptor (CAR) specific for carcinoembryonic antigen (CEA), combined with immune stimulatory cytokines and checkpoint inhibitory molecules, to enhance targeted immune responses and overcome tumor escape mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR-T cell therapy is applied to solid tumors, then tumor targeting capability is improved, but therapeutic efficacy is limited due to immunosuppressive microenvironment and tumor escape mechanisms
Solution Approach 1:
The patent combines multiple functional elements into a single CAR construct: the antigen-binding domain for CEA recognition, a checkpoint inhibitory molecule domain to block immune suppression, and an immune stimulatory cytokine domain to activate immune response. This merging allows the CAR-T cell to simultaneously target tumors, overcome immunosuppression, and stimulate immune activation, thereby resolving the contradiction between targeting capability and therapeutic efficacy.
Solution Approach 2:
The engineered CAR construct performs multiple functions within a single receptor molecule: it recognizes CEA on tumor cells, provides costimulatory signaling through the checkpoint inhibitory molecule domain, and secretes immune stimulatory cytokines. This multi-functionality enables the CAR-T cell to address multiple limitations of solid tumor therapy simultaneously, improving both targeting reliability and overall therapeutic efficacy.
2Productivity
If CAR-T cells are engineered with enhanced immune activation, then therapeutic efficacy is improved, but systemic toxicity and off-target effects increase
Solution Approach 1:
The patent employs a tumor-specific promoter that drives cytokine expression only in CAR-T cells that have recognized and bound to CEA on tumor cells. This ensures that immune stimulatory cytokines are produced locally at the tumor site rather than systemically, thereby enhancing therapeutic efficacy while minimizing systemic toxicity and off-target effects.
Solution Approach 2:
The CAR construct includes a checkpoint inhibitory molecule domain that is constitutively expressed to prevent immunosuppression before it can occur. This preliminary protective action ensures that the CAR-T cells are pre-equipped to resist immune checkpoint-mediated suppression, allowing for safer enhancement of immune activation without proportionally increasing systemic toxicity.
3Reliability
If CAR-T cells target multiple tumor antigens to overcome heterogeneity, then resistance development is reduced, but device complexity increases
Solution Approach 1:
Instead of creating separate CAR constructs for different antigens, the patent merges multiple functional domains into a single CAR molecule: the CEA-specific antigen-binding domain, the checkpoint inhibitory molecule domain, and the immune stimulatory cytokine domain. This approach addresses tumor heterogeneity and resistance through functional diversity rather than antigen diversity, maintaining simplicity while improving reliability.
Data Source
AI summary
Genetically modified cells, including a recombinant nucleic acid expression construct including a first nucleic acid sequence region encoding a chimeric antigen receptor (CAR) that includes an extracellular antigen-binding domain recognizing a carcinoembryonic antigen (CEA) protein, a second nucleic acid sequence region encoding a checkpoint inhibitory molecule, and a third nucleic acid sequence region encoding an immune stimulatory cytokine. In some aspects, the genetically modified cells are T cells or NK cells, preferably cytotoxic T lymphocytes. Anti-CEA CAR-T cells or anti-CEA CAR-NK cells preferentially recognize a membrane-bound CEA protein and express a checkpoint inhibitory molecule and/or an immune stimulatory interleukin in proximity to tumor tissue. Medical use of the cells may relate to treatment of a medical disorder associated with the presence of pathogenic cells expressing CEA, preferably cancer cells, more preferably cancer cells of solid malignancies.